|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1994-11-8
|
|
pubmed:abstractText |
Doxorubicin (5 mg kg-1) was administered intravenously to C57 mice bearing subcutaneous B16F10 melanomas, distributing into the tumour with an area under the concentration-time curve (0-48 h; AUC) of 8.7 micrograms h g-1. Injection of doxorubicin-N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate, containing 5 mg of doxorubicin equivalent per kg, mediated an AUC for free doxorubicin (i.e. doxorubicin released from the conjugate) of 15.2 micrograms h g-1 and for total doxorubicin (i.e. free plus conjugated) of 149.1 micrograms h g-1. An increased dose of doxorubicin-HPMA copolymer conjugate (18 mg of doxorubicin equivalent per kg) produced AUC values of 40.1 micrograms h g-1 and 671.7 micrograms h g-1 for free and total doxorubicin respectively. Hence administration of doxorubicin-HPMA copolymer conjugate achieved rises of 1.7- to 4.6-fold in tumour AUC (free doxorubicin) and 17.19 to 77.0-fold in tumour AUC (total doxorubicin). HPMA copolymers bearing fluorescein isothiocyanate accumulated in vascularised stromal regions, particularly in new growth sites at the tumour periphery. Treatment of mice with doxorubicin-HPMA copolymer conjugate achieved treated/control lifespans up to 320% (three doses of 27 mg of doxorubicin equivalent per kg) compared with only 133% using aggressive regimens of free doxorubicin (3 x 5 mg kg-1).
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-1182701,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-1372863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-1386002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-1525399,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-1754729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-1760851,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-2292138,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-2322298,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-2765631,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-2930589,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-2946403,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-3358905,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-4328913,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-4829199,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917909-5007973
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
636-41
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7917909-Animals,
pubmed-meshheading:7917909-Capillary Permeability,
pubmed-meshheading:7917909-Doxorubicin,
pubmed-meshheading:7917909-Fluorescein-5-isothiocyanate,
pubmed-meshheading:7917909-Injections, Subcutaneous,
pubmed-meshheading:7917909-Macromolecular Substances,
pubmed-meshheading:7917909-Male,
pubmed-meshheading:7917909-Melanoma, Experimental,
pubmed-meshheading:7917909-Methacrylates,
pubmed-meshheading:7917909-Mice,
pubmed-meshheading:7917909-Mice, Inbred Strains,
pubmed-meshheading:7917909-Microscopy, Fluorescence,
pubmed-meshheading:7917909-Neoplasm Transplantation,
pubmed-meshheading:7917909-Prodrugs,
pubmed-meshheading:7917909-Tissue Distribution
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma.
|
|
pubmed:affiliation |
Institute for Cancer Studies, University of Birmingham School of Medicine, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
